Design and Development of Microsomal Prostaglandin E2 Synthase-1 Inhibitors: Challenges and Future Directions

Journal of Medicinal Chemistry

Volumn 59, Issue 13, 2016, Pages 5970-5986

  Koeberle, Andreas ^a   Laufer, Stefan A ^b   Werz, Oliver ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; ARACHIDONATE 5 LIPOXYGENASE; LIPOXYGENASE INHIBITOR; NATURAL PRODUCT; PROSTAGLANDIN E SYNTHASE 1; PROSTAGLANDIN E2 SYNTHASE 1 INHIBITOR; PROSTAGLANDIN SYNTHASE INHIBITOR; UNCLASSIFIED DRUG; ENZYME INHIBITOR; PROSTAGLANDIN E SYNTHASE; PROSTAGLANDIN E2;

COMPUTER MODEL; CRYSTAL STRUCTURE; CRYSTALLIZATION; DRUG BINDING SITE; DRUG DESIGN; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ASSAY; HIGH THROUGHPUT SCREENING; HUMAN; NONHUMAN; PHARMACOPHORE; PLASMA PROTEIN BINDING; REVIEW; STRUCTURE ACTIVITY RELATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; IMMUNOLOGY; INFLAMMATION; MOLECULAR MODEL; PRECLINICAL STUDY; PROCEDURES;

ANIMALS; ANTI-INFLAMMATORY AGENTS; DINOPROSTONE; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INFLAMMATION; MODELS, MOLECULAR; PROSTAGLANDIN-E SYNTHASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84975146978     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b01750     Document Type: Review

References (133)

1. Samuelsson, B.; Morgenstern, R.; Jakobsson, P. J. Membrane prostaglandin E synthase-1: a novel therapeutic target Pharmacol. Rev. 2007, 59, 207-224 10.1124/pr.59.3.1
2. Singh Bahia, M.; Kumar Katare, Y.; Silakari, O.; Vyas, B.; Silakari, P. Inhibitors of microsomal prostaglandin E2 synthase-1 enzyme as emerging anti-inflammatory candidates Med. Res. Rev. 2014, 34, 825-855 10.1002/med.21306
3. Koeberle, A.; Werz, O. Perspective of microsomal prostaglandin E synthase-1 as drug target in inflammation-related disorders Biochem. Pharmacol. 2015, 98, 1-5 10.1016/j.bcp.2015.06.022
4. Hara, S.; Kamei, D.; Sasaki, Y.; Tanemoto, A.; Nakatani, Y.; Murakami, M. Prostaglandin E synthases: Understanding their pathophysiological roles through mouse genetic models Biochimie 2010, 92, 651-659 10.1016/j.biochi.2010.02.007
5. Koeberle, A.; Werz, O. Inhibitors of the microsomal prostaglandin E(2) synthase-1 as alternative to non steroidal anti-inflammatory drugs (NSAIDs) - a critical review Curr. Med. Chem. 2009, 16, 4274-4296 10.2174/092986709789578178
6. Grosser, T.; Yu, Y.; Fitzgerald, G. A. Emotion recollected in tranquility: lessons learned from the COX-2 saga Annu. Rev. Med. 2010, 61, 17-33 10.1146/annurev-med-011209-153129
7. Stables, M. J.; Gilroy, D. W. Old and new generation lipid mediators in acute inflammation and resolution Prog. Lipid Res. 2011, 50, 35-51 10.1016/j.plipres.2010.07.005
8. Murakami, M.; Kudo, I. Prostaglandin E synthase: a novel drug target for inflammation and cancer Curr. Pharm. Des. 2006, 12, 943-954 10.2174/138161206776055912
9. Chang, H. H.; Meuillet, E. J. Identification and development of mPGES-1 inhibitors: where we are at? Future Med. Chem. 2011, 3, 1909-1934 10.4155/fmc.11.136
10. Korotkova, M.; Jakobsson, P. J. Characterization of microsomal prostaglandin E synthase 1 inhibitors Basic Clin. Pharmacol. Toxicol. 2014, 114, 64-69 10.1111/bcpt.12162
11. Scholich, K.; Geisslinger, G. Is mPGES-1 a promising target for pain therapy? Trends Pharmacol. Sci. 2006, 27, 399-401 10.1016/j.tips.2006.06.001
12. Wang, M.; FitzGerald, G. A. Cardiovascular biology of microsomal prostaglandin E synthase-1 Trends Cardiovasc. Med. 2010, 20, 189-195 10.1016/j.tcm.2011.04.002
13. Radmark, O.; Samuelsson, B. Microsomal prostaglandin E synthase-1 and 5-lipoxygenase: potential drug targets in cancer J. Intern. Med. 2010, 268, 5-14 10.1111/j.1365-2796.2010.02246.x
14. Sasaki, Y.; Nakatani, Y.; Hara, S. Role of microsomal prostaglandin E synthase-1 (mPGES-1)-derived prostaglandin E in colon carcinogenesis Prostaglandins Other Lipid Mediators 2015, 121, 42 10.1016/j.prostaglandins.2015.06.006
15. Wang, M.; Ihida-Stansbury, K.; Kothapalli, D.; Tamby, M. C.; Yu, Z.; Chen, L.; Grant, G.; Cheng, Y.; Lawson, J. A.; Assoian, R. K.; Jones, P. L.; Fitzgerald, G. A. Microsomal prostaglandin e2 synthase-1 modulates the response to vascular injury Circulation 2011, 123, 631-639 10.1161/CIRCULATIONAHA.110.973685
16. Chen, L.; Yang, G.; Monslow, J.; Todd, L.; Cormode, D. P.; Tang, J.; Grant, G. R.; DeLong, J. H.; Tang, S. Y.; Lawson, J. A.; Pure, E.; Fitzgerald, G. A. Myeloid cell microsomal prostaglandin E synthase-1 fosters atherogenesis in mice Proc. Natl. Acad. Sci. U. S. A. 2014, 111, 6828-6833 10.1073/pnas.1401797111
17. Chen, L.; Yang, G.; Xu, X.; Grant, G.; Lawson, J. A.; Bohlooly, Y. M.; FitzGerald, G. A. Cell selective cardiovascular biology of microsomal prostaglandin E synthase-1 Circulation 2013, 127, 233-243 10.1161/CIRCULATIONAHA.112.119479
18. Brenneis, C.; Coste, O.; Altenrath, K.; Angioni, C.; Schmidt, H.; Schuh, C. D.; Zhang, D. D.; Henke, M.; Weigert, A.; Brune, B.; Rubin, B.; Nusing, R.; Scholich, K.; Geisslinger, G. Anti-inflammatory role of microsomal prostaglandin E synthase-1 in a model of neuroinflammation J. Biol. Chem. 2011, 286, 2331-2342 10.1074/jbc.M110.157362
19. Frolov, A.; Yang, L.; Dong, H.; Hammock, B. D.; Crofford, L. J. Anti-inflammatory properties of prostaglandin E2: deletion of microsomal prostaglandin E synthase-1 exacerbates non-immune inflammatory arthritis in mice Prostaglandins, Leukotrienes Essent. Fatty Acids 2013, 89, 351-358 10.1016/j.plefa.2013.08.003
20. Soodvilai, S.; Jia, Z.; Wang, M. H.; Dong, Z.; Yang, T. mPGES-1 deletion impairs diuretic response to acute water loading Am. J. Physiol. Renal Physiol. 2009, 296, F1129-1135 10.1152/ajprenal.90478.2008
21. Jia, Z.; Liu, G.; Downton, M.; Dong, Z.; Zhang, A.; Yang, T. mPGES-1 deletion potentiates urine concentrating capability after water deprivation Am. J. Physiol. Renal Physiol. 2012, 302, F1005-1012 10.1152/ajprenal.00508.2011
22. Jia, Z.; Zhang, A.; Zhang, H.; Dong, Z.; Yang, T. Deletion of microsomal prostaglandin E synthase-1 increases sensitivity to salt loading and angiotensin II infusion Circ. Res. 2006, 99, 1243-1251 10.1161/01.RES.0000251306.40546.08
23. Shimizu, T. Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation Annu. Rev. Pharmacol. Toxicol. 2009, 49, 123-150 10.1146/annurev.pharmtox.011008.145616
24. Dennis, E. A.; Cao, J.; Hsu, Y. H.; Magrioti, V.; Kokotos, G. Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention Chem. Rev. 2011, 111, 6130-6185 10.1021/cr200085w
25. Shimizu, T.; Ohto, T.; Kita, Y. Cytosolic phospholipase A2: biochemical properties and physiological roles IUBMB Life 2006, 58, 328-333 10.1080/15216540600702289
26. Shindou, H.; Hishikawa, D.; Harayama, T.; Eto, M.; Shimizu, T. Generation of membrane diversity by lysophospholipid acyltransferases J. Biochem. 2013, 154, 21-28 10.1093/jb/mvt048
27. Mulvihill, M. M.; Nomura, D. K. Therapeutic potential of monoacylglycerol lipase inhibitors Life Sci. 2013, 92, 492-497 10.1016/j.lfs.2012.10.025
28. Blobaum, A. L.; Marnett, L. J. Structural and functional basis of cyclooxygenase inhibition J. Med. Chem. 2007, 50, 1425-1441 10.1021/jm0613166
29. Helliwell, R. J.; Adams, L. F.; Mitchell, M. D. Prostaglandin synthases: recent developments and a novel hypothesis Prostaglandins, Leukotrienes Essent. Fatty Acids 2004, 70, 101-113 10.1016/j.plefa.2003.04.002
30. Tanioka, T.; Nakatani, Y.; Semmyo, N.; Murakami, M.; Kudo, I. Molecular identification of cytosolic prostaglandin E2 synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E2 biosynthesis J. Biol. Chem. 2000, 275, 32775-32782 10.1074/jbc.M003504200
31. Sanchez, E. R. Chaperoning steroidal physiology: lessons from mouse genetic models of Hsp90 and its cochaperones Biochim. Biophys. Acta, Mol. Cell Res. 2012, 1823, 722-729 10.1016/j.bbamcr.2011.11.006
32. Jania, L. A.; Chandrasekharan, S.; Backlund, M. G.; Foley, N. A.; Snouwaert, J.; Wang, I. M.; Clark, P.; Audoly, L. P.; Koller, B. H. Microsomal prostaglandin E synthase-2 is not essential for in vivo prostaglandin E2 biosynthesis Prostaglandins Other Lipid Mediators 2009, 88, 73-81 10.1016/j.prostaglandins.2008.10.003
33. Takusagawa, F. Microsomal prostaglandin E synthase type 2 (mPGES2) is a glutathione-dependent heme protein, and dithiothreitol dissociates the bound heme to produce active prostaglandin E2 synthase in vitro J. Biol. Chem. 2013, 288, 10166-10175 10.1074/jbc.M112.418475
34. Chaudhry, U.; Zhuang, H.; Dore, S. Microsomal prostaglandin E synthase-2: cellular distribution and expression in Alzheimer's disease Exp. Neurol. 2010, 223, 359-365 10.1016/j.expneurol.2009.07.027
35. Schneider, A.; Zhang, Y.; Zhang, M.; Lu, W. J.; Rao, R.; Fan, X.; Redha, R.; Davis, L.; Breyer, R. M.; Harris, R.; Guan, Y.; Breyer, M. D. Membrane-associated PGE synthase-1 (mPGES-1) is coexpressed with both COX-1 and COX-2 in the kidney Kidney Int. 2004, 65, 1205-1213 10.1111/j.1523-1755.2004.00493.x
36. Folco, G.; Murphy, R. C. Eicosanoid transcellular biosynthesis: from cell-cell interactions to in vivo tissue responses Pharmacol. Rev. 2006, 58, 375-388 10.1124/pr.58.3.8
37. Xiao, L.; Ornatowska, M.; Zhao, G.; Cao, H.; Yu, R.; Deng, J.; Li, Y.; Zhao, Q.; Sadikot, R. T.; Christman, J. W. Lipopolysaccharide-induced expression of microsomal prostaglandin E synthase-1 mediates late-phase PGE2 production in bone marrow derived macrophages PLoS One 2012, 7, e50244 10.1371/journal.pone.0050244
38. Mancini, A. D.; Di Battista, J. A. The cardinal role of the phospholipase A(2)/cyclooxygenase-2/prostaglandin E synthase/prostaglandin E(2) (PCPP) axis in inflammostasis Inflammation Res. 2011, 60, 1083-1092 10.1007/s00011-011-0385-7
39. Levy, B. D.; Clish, C. B.; Schmidt, B.; Gronert, K.; Serhan, C. N. Lipid mediator class switching during acute inflammation: signals in resolution Nat. Immunol. 2001, 2, 612-619 10.1038/89759
40. Idborg, H.; Olsson, P.; Leclerc, P.; Raouf, J.; Jakobsson, P. J.; Korotkova, M. Effects of mPGES-1 deletion on eicosanoid and fatty acid profiles in mice Prostaglandins Other Lipid Mediators 2013, 107, 18-25 10.1016/j.prostaglandins.2013.07.004
41. Jakobsson, P. J.; Thoren, S.; Morgenstern, R.; Samuelsson, B. Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target Proc. Natl. Acad. Sci. U. S. A. 1999, 96, 7220-7225 10.1073/pnas.96.13.7220
42. Hamza, A.; Tong, M.; AbdulHameed, M. D.; Liu, J.; Goren, A. C.; Tai, H. H.; Zhan, C. G. Understanding microscopic binding of human microsomal prostaglandin E synthase-1 (mPGES-1) trimer with substrate PGH2 and cofactor GSH: insights from computational alanine scanning and site-directed mutagenesis J. Phys. Chem. B 2010, 114, 5605-5616 10.1021/jp100668y
43. Xing, L.; Kurumbail, R. G.; Frazier, R. B.; Davies, M. S.; Fujiwara, H.; Weinberg, R. A.; Gierse, J. K.; Caspers, N.; Carter, J. S.; McDonald, J. J.; Moore, W. M.; Vazquez, M. L. Homo-timeric structural model of human microsomal prostaglandin E synthase-1 and characterization of its substrate/inhibitor binding interactions J. Comput.-Aided Mol. Des. 2009, 23, 13-24 10.1007/s10822-008-9233-4
44. Holm, P. J.; Morgenstern, R.; Hebert, H. The 3-D structure of microsomal glutathione transferase 1 at 6 A resolution as determined by electron crystallography of p22(1)2(1) crystals Biochim. Biophys. Acta, Protein Struct. Mol. Enzymol. 2002, 1594, 276-285 10.1016/S0167-4838(01)00311-9
45. Jegerschold, C.; Pawelzik, S. C.; Purhonen, P.; Bhakat, P.; Gheorghe, K. R.; Gyobu, N.; Mitsuoka, K.; Morgenstern, R.; Jakobsson, P. J.; Hebert, H. Structural basis for induced formation of the inflammatory mediator prostaglandin E2 Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 11110-11115 10.1073/pnas.0802894105
46. Sjogren, T.; Nord, J.; Ek, M.; Johansson, P.; Liu, G.; Geschwindner, S. Crystal structure of microsomal prostaglandin E2 synthase provides insight into diversity in the MAPEG superfamily Proc. Natl. Acad. Sci. U. S. A. 2013, 110, 3806-3811 10.1073/pnas.1218504110
47. Ferguson, A. D.; McKeever, B. M.; Xu, S.; Wisniewski, D.; Miller, D. K.; Yamin, T. T.; Spencer, R. H.; Chu, L.; Ujjainwalla, F.; Cunningham, B. R.; Evans, J. F.; Becker, J. W. Crystal structure of inhibitor-bound human 5-lipoxygenase-activating protein Science 2007, 317, 510-512 10.1126/science.1144346
48. Molina, D. M.; Wetterholm, A.; Kohl, A.; McCarthy, A. A.; Niegowski, D.; Ohlson, E.; Hammarberg, T.; Eshaghi, S.; Haeggstrom, J. Z.; Nordlund, P. Structural basis for synthesis of inflammatory mediators by human leukotriene C4 synthase Nature 2007, 448, 613-616 10.1038/nature06009
49. Pawelzik, S. C.; Uda, N. R.; Spahiu, L.; Jegerschold, C.; Stenberg, P.; Hebert, H.; Morgenstern, R.; Jakobsson, P. J. Identification of key residues determining species differences in inhibitor binding of microsomal prostaglandin E synthase-1 J. Biol. Chem. 2010, 285, 29254-29261 10.1074/jbc.M110.114454
50. Ago, H.; Kanaoka, Y.; Irikura, D.; Lam, B. K.; Shimamura, T.; Austen, K. F.; Miyano, M. Crystal structure of a human membrane protein involved in cysteinyl leukotriene biosynthesis Nature 2007, 448, 609-612 10.1038/nature05936
51. He, S.; Wu, Y.; Yu, D.; Lai, L. Microsomal prostaglandin E synthase-1 exhibits one-third-of-the-sites reactivity Biochem. J. 2011, 440, 13-21 10.1042/BJ20110977
52. Hammarberg, T.; Hamberg, M.; Wetterholm, A.; Hansson, H.; Samuelsson, B.; Haeggstrom, J. Z. Mutation of a critical arginine in microsomal PGE synthase-1 shifts the isomerase activity to a reductase activity that converts prostaglandin H2 into prostaglandin F2alpha J. Biol. Chem. 2009, 284, 301-305 10.1074/jbc.M808365200
53. Norberg, J. K.; Sells, E.; Chang, H. H.; Alla, S. R.; Zhang, S.; Meuillet, E. J. Targeting inflammation: multiple innovative ways to reduce prostaglandin E(2) Pharm. Pat. Anal. 2013, 2, 265-288 10.4155/ppa.12.90
54. Jin, Y.; Smith, C. L.; Hu, L.; Campanale, K. M.; Stoltz, R.; Huffman, L. G., Jr.; McNearney, T. A.; Yang, X. Y.; Ackermann, B. L.; Dean, R.; Regev, A.; Landschulz, W. Pharmacodynamic comparison of LY3023703, a novel microsomal prostaglandin E synthase 1 inhibitor, with celecoxib Clin. Pharmacol. Ther. 2015, 10.1002/cpt.260
55. Thoren, S.; Jakobsson, P. J. Coordinate up- and down-regulation of glutathione-dependent prostaglandin E synthase and cyclooxygenase-2 in A549 cells. Inhibition by NS-398 and leukotriene C4 Eur. J. Biochem. 2000, 267, 6428-6434 10.1046/j.1432-1327.2000.01735.x
56. David Percival, M. Continuous spectrophotometric assay amenable to 96-well plate format for prostaglandin E synthase activity Anal. Biochem. 2003, 313, 307-310 10.1016/S0003-2697(02)00615-2
57. Choi, K. A.; Park, S. J.; Yu, Y. G. Development of a coupled enzyme assay method for microsomal prostaglandin E synthase activity Bull. Korean Chem. Soc. 2010, 31, 384-388 10.5012/bkcs.2010.31.02.384
58. Wiegard, A.; Hanekamp, W.; Griessbach, K.; Fabian, J.; Lehr, M. Pyrrole alkanoic acid derivatives as nuisance inhibitors of microsomal prostaglandin E2 synthase-1 Eur. J. Med. Chem. 2012, 48, 153-163 10.1016/j.ejmech.2011.12.009
59. Masse, F.; Guiral, S.; Fortin, L. J.; Cauchon, E.; Ethier, D.; Guay, J.; Brideau, C. An automated multistep high-throughput screening assay for the identification of lead inhibitors of the inducible enzyme mPGES-1 J. Biomol. Screening 2005, 10, 599-605 10.1177/1087057105276083
60. Goedken, E. R.; Gagnon, A. I.; Overmeyer, G. T.; Liu, J.; Petrillo, R. A.; Burchat, A. F.; Tomlinson, M. J. HTRF-based assay for microsomal prostaglandin E2 synthase-1 activity J. Biomol. Screening 2008, 13, 619-625 10.1177/1087057108321145
61. Spahiu, L.; Stenberg, P.; Larsson, C.; Wannberg, J.; Alterman, M.; Kull, B.; Nekhotiaeva, N.; Morgenstern, R. A facilitated approach to evaluate the inhibitor mode and potency of compounds targeting microsomal prostaglandin e synthase-1 Assay Drug Dev. Technol. 2011, 9, 487-495 10.1089/adt.2010.0350
62. Andersson, S.; Norman, M.; Olsson, R.; Smith, R.; Liu, G.; Nord, J. High-precision, room temperature screening assay for inhibitors of microsomal prostaglandin E synthase-1 J. Biomol. Screening 2012, 17, 1372-1378 10.1177/1087057112456424
63. Leveridge, M. V.; Bardera, A. I.; LaMarr, W.; Billinton, A.; Bellenie, B.; Edge, C.; Francis, P.; Christodoulou, E.; Shillings, A.; Hibbs, M.; Fosberry, A.; Tanner, R.; Hardwicke, P.; Craggs, P.; Sinha, Y.; Elegbe, O.; Alvarez-Ruiz, E.; Martin-Plaza, J. J.; Barroso-Poveda, V.; Baddeley, S.; Chung, C. W.; Hutchinson, J. Lead discovery for microsomal prostaglandin E synthase using a combination of high-throughput fluorescent-based assays and RapidFire mass spectrometry J. Biomol. Screening 2012, 17, 641-650 10.1177/1087057111435700
64. Murakami, M.; Nakatani, Y.; Tanioka, T.; Kudo, I. Prostaglandin E synthase Prostaglandins Other Lipid Mediators 2002, 68-69, 383-399 10.1016/S0090-6980(02)00043-6
65. Rorsch, F.; Wobst, I.; Zettl, H.; Schubert-Zsilavecz, M.; Grosch, S.; Geisslinger, G.; Schneider, G.; Proschak, E. Nonacidic inhibitors of human microsomal prostaglandin synthase 1 (mPGES 1) identified by a multistep virtual screening protocol J. Med. Chem. 2010, 53, 911-915 10.1021/jm9012505
66. Waltenberger, B.; Wiechmann, K.; Bauer, J.; Markt, P.; Noha, S. M.; Wolber, G.; Rollinger, J. M.; Werz, O.; Schuster, D.; Stuppner, H. Pharmacophore modeling and virtual screening for novel acidic inhibitors of microsomal prostaglandin E(2) synthase-1 (mPGES-1) J. Med. Chem. 2011, 54, 3163-3174 10.1021/jm101309g
67. Hamza, A.; Zhao, X.; Tong, M.; Tai, H. H.; Zhan, C. G. Novel human mPGES-1 inhibitors identified through structure-based virtual screening Bioorg. Med. Chem. 2011, 19, 6077-6086 10.1016/j.bmc.2011.08.040
68. De Simone, R.; Chini, M. G.; Bruno, I.; Riccio, R.; Mueller, D.; Werz, O.; Bifulco, G. Structure-based discovery of inhibitors of microsomal prostaglandin E2 synthase-1, 5-lipoxygenase and 5-lipoxygenase-activating protein: promising hits for the development of new anti-inflammatory agents J. Med. Chem. 2011, 54, 1565-1575 10.1021/jm101238d
69. He, S.; Li, C.; Liu, Y.; Lai, L. Discovery of highly potent microsomal prostaglandin e2 synthase 1 inhibitors using the active conformation structural model and virtual screen J. Med. Chem. 2013, 56, 3296-3309 10.1021/jm301900x
70. Lauro, G.; Strocchia, M.; Terracciano, S.; Bruno, I.; Fischer, K.; Pergola, C.; Werz, O.; Riccio, R.; Bifulco, G. Exploration of the dihydropyrimidine scaffold for the development of new potential anti-inflammatory agents blocking prostaglandin E(2) synthase-1 enzyme (mPGES-1) Eur. J. Med. Chem. 2014, 80, 407-415 10.1016/j.ejmech.2014.04.061
71. Quraishi, O.; Mancini, J. A.; Riendeau, D. Inhibition of inducible prostaglandin E(2) synthase by 15-deoxy-Delta(12,14)-prostaglandin J(2) and polyunsaturated fatty acids Biochem. Pharmacol. 2002, 63, 1183-1189 10.1016/S0006-2952(02)00844-4
72. Futaki, N.; Yoshikawa, K.; Hamasaka, Y.; Arai, I.; Higuchi, S.; Iizuka, H.; Otomo, S. NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions Gen. Pharmacol. 1993, 24, 105-110 10.1016/0306-3623(93)90018-S
73. Elkady, M.; Niess, R.; Schaible, A. M.; Bauer, J.; Luderer, S.; Ambrosi, G.; Werz, O.; Laufer, S. A. Modified acidic nonsteroidal anti-inflammatory drugs as dual inhibitors of mPGES-1 and 5-LOX J. Med. Chem. 2012, 55, 8958-8962 10.1021/jm3010543
74. Gillard, J.; Ford-Hutchinson, A. W.; Chan, C.; Charleson, S.; Denis, D.; Foster, A.; Fortin, R.; Leger, S.; McFarlane, C. S.; Morton, H. et al. L-663,536 (MK-886) (3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2-dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitor Can. J. Physiol. Pharmacol. 1989, 67, 456-464 10.1139/y89-073
75. Mancini, J. A.; Blood, K.; Guay, J.; Gordon, R.; Claveau, D.; Chan, C. C.; Riendeau, D. Cloning, expression, and up-regulation of inducible rat prostaglandin e synthase during lipopolysaccharide-induced pyresis and adjuvant-induced arthritis J. Biol. Chem. 2001, 276, 4469-4475 10.1074/jbc.M006865200
76. Claveau, D.; Sirinyan, M.; Guay, J.; Gordon, R.; Chan, C. C.; Bureau, Y.; Riendeau, D.; Mancini, J. A. Microsomal prostaglandin E synthase-1 is a major terminal synthase that is selectively up-regulated during cyclooxygenase-2-dependent prostaglandin E2 production in the rat adjuvant-induced arthritis model J. Immunol. 2003, 170, 4738-4744 10.4049/jimmunol.170.9.4738
77. Riendeau, D.; Aspiotis, R.; Ethier, D.; Gareau, Y.; Grimm, E. L.; Guay, J.; Guiral, S.; Juteau, H.; Mancini, J. A.; Methot, N.; Rubin, J.; Friesen, R. W. Inhibitors of the inducible microsomal prostaglandin E2 synthase (mPGES-1) derived from MK-886 Bioorg. Med. Chem. Lett. 2005, 15, 3352-3355 10.1016/j.bmcl.2005.05.027
78. Koeberle, A.; Siemoneit, U.; Buhring, U.; Northoff, H.; Laufer, S.; Albrecht, W.; Werz, O. Licofelone suppresses prostaglandin E2 formation by interference with the inducible microsomal prostaglandin E2 synthase-1 J. Pharmacol. Exp. Ther. 2008, 326, 975-982 10.1124/jpet.108.139444
79. Koeberle, A.; Siemoneit, U.; Northoff, H.; Hofmann, B.; Schneider, G.; Werz, O. MK-886, an inhibitor of the 5-lipoxygenase-activating protein, inhibits cyclooxygenase-1 activity and suppresses platelet aggregation Eur. J. Pharmacol. 2009, 608, 84-90 10.1016/j.ejphar.2009.02.023
80. Cote, B.; Boulet, L.; Brideau, C.; Claveau, D.; Ethier, D.; Frenette, R.; Gagnon, M.; Giroux, A.; Guay, J.; Guiral, S.; Mancini, J.; Martins, E.; Masse, F.; Methot, N.; Riendeau, D.; Rubin, J.; Xu, D.; Yu, H.; Ducharme, Y.; Friesen, R. W. Substituted phenanthrene imidazoles as potent, selective, and orally active mPGES-1 inhibitors Bioorg. Med. Chem. Lett. 2007, 17, 6816-6820 10.1016/j.bmcl.2007.10.033
81. Xu, D.; Rowland, S. E.; Clark, P.; Giroux, A.; Cote, B.; Guiral, S.; Salem, M.; Ducharme, Y.; Friesen, R. W.; Methot, N.; Mancini, J.; Audoly, L.; Riendeau, D. MF63 [2-(6-chloro-1H-phenanthro[9,10-d]imidazol-2-yl)-isophthalonitrile], a selective microsomal prostaglandin E synthase-1 inhibitor, relieves pyresis and pain in preclinical models of inflammation J. Pharmacol. Exp. Ther. 2008, 326, 754-763 10.1124/jpet.108.138776
82. Giroux, A.; Boulet, L.; Brideau, C.; Chau, A.; Claveau, D.; Cote, B.; Ethier, D.; Frenette, R.; Gagnon, M.; Guay, J.; Guiral, S.; Mancini, J.; Martins, E.; Masse, F.; Methot, N.; Riendeau, D.; Rubin, J.; Xu, D.; Yu, H.; Ducharme, Y.; Friesen, R. W. Discovery of disubstituted phenanthrene imidazoles as potent, selective and orally active mPGES-1 inhibitors Bioorg. Med. Chem. Lett. 2009, 19, 5837-5841 10.1016/j.bmcl.2009.08.085
83. Wu, T. Y.; Juteau, H.; Ducharme, Y.; Friesen, R. W.; Guiral, S.; Dufresne, L.; Poirier, H.; Salem, M.; Riendeau, D.; Mancini, J.; Brideau, C. Biarylimidazoles as inhibitors of microsomal prostaglandin E2 synthase-1 Bioorg. Med. Chem. Lett. 2010, 20, 6978-6982 10.1016/j.bmcl.2010.09.129
84. Chiasson, J. F.; Boulet, L.; Brideau, C.; Chau, A.; Claveau, D.; Cote, B.; Ethier, D.; Giroux, A.; Guay, J.; Guiral, S.; Mancini, J.; Masse, F.; Methot, N.; Riendeau, D.; Roy, P.; Rubin, J.; Xu, D.; Yu, H.; Ducharme, Y.; Friesen, R. W. Trisubstituted ureas as potent and selective mPGES-1 inhibitors Bioorg. Med. Chem. Lett. 2011, 21, 1488-1492 10.1016/j.bmcl.2011.01.006
85. Wang, J.; Limburg, D.; Carter, J.; Mbalaviele, G.; Gierse, J.; Vazquez, M. Selective inducible microsomal prostaglandin E(2) synthase-1 (mPGES-1) inhibitors derived from an oxicam template Bioorg. Med. Chem. Lett. 2010, 20, 1604-1609 10.1016/j.bmcl.2010.01.060
86. Arhancet, G. B.; Walker, D. P.; Metz, S.; Fobian, Y. M.; Heasley, S. E.; Carter, J. S.; Springer, J. R.; Jones, D. E.; Hayes, M. J.; Shaffer, A. F.; Jerome, G. M.; Baratta, M. T.; Zweifel, B.; Moore, W. M.; Masferrer, J. L.; Vazquez, M. L. Discovery and SAR of PF-4693627, a potent, selective and orally bioavailable mPGES-1 inhibitor for the potential treatment of inflammation Bioorg. Med. Chem. Lett. 2013, 23, 1114-1119 10.1016/j.bmcl.2012.11.109
87. Walker, D. P.; Arhancet, G. B.; Lu, H. F.; Heasley, S. E.; Metz, S.; Kablaoui, N. M.; Franco, F. M.; Hanau, C. E.; Scholten, J. A.; Springer, J. R.; Fobian, Y. M.; Carter, J. S.; Xing, L.; Yang, S.; Shaffer, A. F.; Jerome, G. M.; Baratta, M. T.; Moore, W. M.; Vazquez, M. L. Synthesis and biological evaluation of substituted benzoxazoles as inhibitors of mPGES-1: use of a conformation-based hypothesis to facilitate compound design Bioorg. Med. Chem. Lett. 2013, 23, 1120-1126 10.1016/j.bmcl.2012.11.107
88. Shiro, T.; Takahashi, H.; Kakiguchi, K.; Inoue, Y.; Masuda, K.; Nagata, H.; Tobe, M. Synthesis and SAR study of imidazoquinolines as a novel structural class of microsomal prostaglandin E(2) synthase-1 inhibitors Bioorg. Med. Chem. Lett. 2012, 22, 285-288 10.1016/j.bmcl.2011.11.015
89. Shiro, T.; Kakiguchi, K.; Takahashi, H.; Nagata, H.; Tobe, M. Synthesis and biological evaluation of substituted imidazoquinoline derivatives as mPGES-1 inhibitors Bioorg. Med. Chem. 2013, 21, 2068-2078 10.1016/j.bmc.2013.01.018
90. Shiro, T.; Kakiguchi, K.; Takahashi, H.; Nagata, H.; Tobe, M. 7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors Bioorg. Med. Chem. 2013, 21, 2868-2878 10.1016/j.bmc.2013.03.069
91. Banerjee, A.; Pawar, M. Y.; Patil, S.; Yadav, P. S.; Kadam, P. A.; Kattige, V. G.; Deshpande, D. S.; Pednekar, P. V.; Pisat, M. K.; Gharat, L. A. Development of 2-aryl substituted quinazolin-4(3H)-one, pyrido[4,3-d]pyrimidin-4(3H)-one and pyrido[2,3-d]pyrimidin-4(3H)-one derivatives as microsomal prostaglandin E(2) synthase-1 inhibitors Bioorg. Med. Chem. Lett. 2014, 24, 4838-4844 10.1016/j.bmcl.2014.08.056
92. Hughes, N. E.; Norman, B. H.; Woods, T. A. Novel imidazole derivatives useful for the treatment of arthritis. PCT Intl. Appl. WO/2012/161965, 2012.
93. Pfau, R.; Arndt, K.; Doods, K. K.; Kuelzer, R.; Lubriks, D.; Mack, J.; Pelcman, P.; Priepke, H.; Roenn, R.; Stenkamp, D.; Weniger, S. E. 3h-imidazo [4, 5 -c] pyridine- 6 -carboxamides as anti- inflammatory agents. PCT Intl. Appl. WO/2010/100249, 2010.
94. Otsnu, H. Preparation of compounds as inhibitors of microsomal prostaglandin E synthase-1 (mPGES-1). PCT Intl. Appl. WO/2013/024898, 2013.
95. Eli Lilly and Company. A Study of LY3023703 Testing Pain Relief after Wisdom Teeth Removal. NCT01872910 https://clinicaltrials.gov/, 2013.
96. Koeberle, A.; Pollastro, F.; Northoff, H.; Werz, O. Myrtucommulone, a natural acylphloroglucinol, inhibits microsomal prostaglandin E(2) synthase-1 Br. J. Pharmacol. 2009, 156, 952-961 10.1111/j.1476-5381.2009.00070.x
97. Koeberle, A.; Rossi, A.; Bauer, J.; Dehm, F.; Verotta, L.; Northoff, H.; Sautebin, L.; Werz, O. Hyperforin, an anti-Inflammatory constituent from St. John's wort, inhibits microsomal prostaglandin E(2) synthase-1 and suppresses prostaglandin E(2) formation in vivo Front. Pharmacol. 2011, 2, 7 10.3389/fphar.2011.00007
98. Bauer, J.; Koeberle, A.; Dehm, F.; Pollastro, F.; Appendino, G.; Northoff, H.; Rossi, A.; Sautebin, L.; Werz, O. Arzanol, a prenylated heterodimeric phloroglucinyl pyrone, inhibits eicosanoid biosynthesis and exhibits anti-inflammatory efficacy in vivo Biochem. Pharmacol. 2011, 81, 259-268 10.1016/j.bcp.2010.09.025
99. Koeberle, A.; Bauer, J.; Verhoff, M.; Hoffmann, M.; Northoff, H.; Werz, O. Green tea epigallocatechin-3-gallate inhibits microsomal prostaglandin E(2) synthase-1 Biochem. Biophys. Res. Commun. 2009, 388, 350-354 10.1016/j.bbrc.2009.08.005
100. Koeberle, A.; Northoff, H.; Werz, O. Curcumin blocks prostaglandin E2 biosynthesis through direct inhibition of the microsomal prostaglandin E2 synthase-1 Mol. Cancer Ther. 2009, 8, 2348-2355 10.1158/1535-7163.MCT-09-0290
101. Bauer, J.; Waltenberger, B.; Noha, S. M.; Schuster, D.; Rollinger, J. M.; Boustie, J.; Chollet, M.; Stuppner, H.; Werz, O. Discovery of depsides and depsidones from lichen as potent inhibitors of microsomal prostaglandin E2 synthase-1 using pharmacophore models ChemMedChem 2012, 7, 2077-2081 10.1002/cmdc.201200345
102. Bauer, J.; Kuehnl, S.; Rollinger, J. M.; Scherer, O.; Northoff, H.; Stuppner, H.; Werz, O.; Koeberle, A. Carnosol and carnosic acids from Salvia officinalis inhibit microsomal prostaglandin E2 synthase-1 J. Pharmacol. Exp. Ther. 2012, 342, 169-176 10.1124/jpet.112.193847
103. Schaible, A. M.; Traber, H.; Temml, V.; Noha, S. M.; Filosa, R.; Peduto, A.; Weinigel, C.; Barz, D.; Schuster, D.; Werz, O. Potent inhibition of human 5-lipoxygenase and microsomal prostaglandin E(2) synthase-1 by the anti-carcinogenic and anti-inflammatory agent embelin Biochem. Pharmacol. 2013, 86, 476-486 10.1016/j.bcp.2013.04.015
104. Siemoneit, U.; Koeberle, A.; Rossi, A.; Dehm, F.; Verhoff, M.; Reckel, S.; Maier, T. J.; Jauch, J.; Northoff, H.; Bernhard, F.; Doetsch, V.; Sautebin, L.; Werz, O. Inhibition of microsomal prostaglandin E2 synthase-1 as a molecular basis for the anti-inflammatory actions of boswellic acids from frankincense Br. J. Pharmacol. 2011, 162, 147-162 10.1111/j.1476-5381.2010.01020.x
105. Verhoff, M.; Seitz, S.; Paul, M.; Noha, S. M.; Jauch, J.; Schuster, D.; Werz, O. Tetra- and pentacyclic triterpene acids from the ancient anti-inflammatory remedy frankincense as inhibitors of microsomal prostaglandin E(2) synthase-1 J. Nat. Prod. 2014, 77, 1445-1451 10.1021/np500198g
106. Laufer, S. A.; Augustin, J.; Dannhardt, G.; Kiefer, W. (6,7-Diaryldihydropyrrolizin-5-yl)acetic acids, a novel class of potent dual inhibitors of both cyclooxygenase and 5-lipoxygenase J. Med. Chem. 1994, 37, 1894-1897 10.1021/jm00038a021
107. Wallace, J. L.; Carter, L.; McKnight, W.; Tries, S.; Laufer, S. ML 3000 reduces gastric prostaglandin synthesis without causing mucosal injury Eur. J. Pharmacol. 1994, 271, 525-531 10.1016/0014-2999(94)90814-1
108. Fischer, L.; Hornig, M.; Pergola, C.; Meindl, N.; Franke, L.; Tanrikulu, Y.; Dodt, G.; Schneider, G.; Steinhilber, D.; Werz, O. The molecular mechanism of the inhibition by licofelone of the biosynthesis of 5-lipoxygenase products Br. J. Pharmacol. 2007, 152, 471-480 10.1038/sj.bjp.0707416
109. Kulkarni, S. K.; Singh, V. P. Licofelone - a novel analgesic and anti-inflammatory agent Curr. Top. Med. Chem. 2007, 7, 251-263 10.2174/156802607779941305
110. Liedtke, A. J.; Keck, P. R.; Lehmann, F.; Koeberle, A.; Werz, O.; Laufer, S. A. Arylpyrrolizines as inhibitors of microsomal prostaglandin E2 synthase-1 (mPGES-1) or as dual inhibitors of mPGES-1 and 5-lipoxygenase (5-LOX) J. Med. Chem. 2009, 52, 4968-4972 10.1021/jm900481c
111. Koeberle, A.; Zettl, H.; Greiner, C.; Wurglics, M.; Schubert-Zsilavecz, M.; Werz, O. Pirinixic acid derivatives as novel dual inhibitors of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase J. Med. Chem. 2008, 51, 8068-8076 10.1021/jm801085s
112. Koeberle, A.; Rossi, A.; Zettl, H.; Pergola, C.; Dehm, F.; Bauer, J.; Greiner, C.; Reckel, S.; Hoernig, C.; Northoff, H.; Bernhard, F.; Dotsch, V.; Sautebin, L.; Schubert-Zsilavecz, M.; Werz, O. The molecular pharmacology and in vivo activity of 2-(4-chloro-6-(2,3-dimethylphenylamino)pyrimidin-2-ylthio)octanoic acid (YS121), a dual inhibitor of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase J. Pharmacol. Exp. Ther. 2010, 332, 840-848 10.1124/jpet.109.160663
113. Hieke, M.; Greiner, C.; Dittrich, M.; Reisen, F.; Schneider, G.; Schubert-Zsilavecz, M.; Werz, O. Discovery and biological evaluation of a novel class of dual microsomal prostaglandin E2 synthase-1/5-lipoxygenase inhibitors based on 2-[(4,6-diphenethoxypyrimidin-2-yl)thio]hexanoic acid J. Med. Chem. 2011, 54, 4490-4507 10.1021/jm200092b
114. Hanke, T.; Dehm, F.; Liening, S.; Popella, S. D.; Maczewsky, J.; Pillong, M.; Kunze, J.; Weinigel, C.; Barz, D.; Kaiser, A.; Wurglics, M.; Lammerhofer, M.; Schneider, G.; Sautebin, L.; Schubert-Zsilavecz, M.; Werz, O. Aminothiazole-featured pirinixic acid derivatives as dual 5-lipoxygenase and microsomal prostaglandin E2 synthase-1 inhibitors with improved potency and efficiency in vivo J. Med. Chem. 2013, 56, 9031-9044 10.1021/jm401557w
115. Merk, D.; Zettl, M.; Steinhilber, D.; Werz, O.; Schubert-Zsilavecz, M. Pirinixic acids: flexible fatty acid mimetics with various biological activities Future Med. Chem. 2015, 7, 1597-1616 10.4155/fmc.15.87
116. Karg, E. M.; Luderer, S.; Pergola, C.; Buhring, U.; Rossi, A.; Northoff, H.; Sautebin, L.; Troschutz, R.; Werz, O. Structural optimization and biological evaluation of 2-substituted 5-hydroxyindole-3-carboxylates as potent inhibitors of human 5-lipoxygenase J. Med. Chem. 2009, 52, 3474-3483 10.1021/jm900212y
117. Koeberle, A.; Haberl, E. M.; Rossi, A.; Pergola, C.; Dehm, F.; Northoff, H.; Troschuetz, R.; Sautebin, L.; Werz, O. Discovery of benzo[g]indol-3-carboxylates as potent inhibitors of microsomal prostaglandin E(2) synthase-1 Bioorg. Med. Chem. 2009, 17, 7924-7932 10.1016/j.bmc.2009.10.025
118. Shang, E.; Wu, Y.; Liu, P.; Liu, Y.; Zhu, W.; Deng, X.; He, C.; He, S.; Li, C.; Lai, L. Benzo[d]isothiazole 1,1-dioxide derivatives as dual functional inhibitors of 5-lipoxygenase and microsomal prostaglandin E(2) synthase-1 Bioorg. Med. Chem. Lett. 2014, 24, 2764-2767 10.1016/j.bmcl.2014.04.006
119. Wiechmann, K.; Muller, H.; Huch, V.; Hartmann, D.; Werz, O.; Jauch, J. Synthesis and biological evaluation of novel myrtucommulones and structural analogues that target mPGES-1 and 5-lipoxygenase Eur. J. Med. Chem. 2015, 101, 133-149 10.1016/j.ejmech.2015.06.001
120. Koeberle, A.; Munoz, E.; Appendino, G. B.; Minassi, A.; Pace, S.; Rossi, A.; Weinigel, C.; Barz, D.; Sautebin, L.; Caprioglio, D.; Collado, J. A.; Werz, O. SAR studies on curcumin's pro-inflammatory targets: discovery of prenylated pyrazolocurcuminoids as potent and selective novel inhibitors of 5-lipoxygenase J. Med. Chem. 2014, 57, 5638-5648 10.1021/jm500308c
121. Filosa, R.; Peduto, A.; Schaible, A. M.; Krauth, V.; Weinigel, C.; Barz, D.; Petronzi, C.; Bruno, F.; Roviezzo, F.; Spaziano, G.; D'Agostino, B.; De Rosa, M.; Werz, O. Novel series of benzoquinones with high potency against 5-lipoxygenase in human polymorphonuclear leukocytes Eur. J. Med. Chem. 2015, 94, 132-139 10.1016/j.ejmech.2015.02.042
122. Prage, E. B.; Pawelzik, S. C.; Busenlehner, L. S.; Kim, K.; Morgenstern, R.; Jakobsson, P. J.; Armstrong, R. N. Location of inhibitor binding sites in the human inducible prostaglandin E synthase, MPGES1 Biochemistry 2011, 50, 7684-7693 10.1021/bi2010448
123. Prage, E. B.; Morgenstern, R.; Jakobsson, P. J.; Stec, D. F.; Voehler, M. W.; Armstrong, R. N. Observation of two modes of inhibition of human microsomal prostaglandin E synthase 1 by the cyclopentenone 15-deoxy-delta(12,14)-prostaglandin J(2) Biochemistry 2012, 51, 2348-2356 10.1021/bi2019332
124. Luz, J. G.; Antonysamy, S.; Kuklish, S. L.; Condon, B.; Lee, M. R.; Allison, D.; Yu, X. P.; Chandrasekhar, S.; Backer, R.; Zhang, A.; Russell, M.; Chang, S. S.; Harvey, A.; Sloan, A. V.; Fisher, M. J. Crystal structures of mPGES-1 inhibitor complexes form a basis for the rational design of potent analgesic and anti-inflammatory therapeutics J. Med. Chem. 2015, 58, 4727-4737 10.1021/acs.jmedchem.5b00330
125. Li, D.; Howe, N.; Dukkipati, A.; Shah, S. T.; Bax, B. D.; Edge, C.; Bridges, A.; Hardwicke, P.; Singh, O. M.; Giblin, G.; Pautsch, A.; Pfau, R.; Schnapp, G.; Wang, M.; Olieric, V.; Caffrey, M. Crystallizing membrane proteins in the lipidic mesophase. Experience with human prostaglandin E2 synthase 1 and an evolving strategy Cryst. Growth Des. 2014, 14, 2034-2047 10.1021/cg500157x
126. Yamada, M.; Kita, Y.; Kohira, T.; Yoshida, K.; Hamano, F.; Tokuoka, S. M.; Shimizu, T. A comprehensive quantification method for eicosanoids and related compounds by using liquid chromatography/mass spectrometry with high speed continuous ionization polarity switching J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2015, 995-996, 74-84 10.1016/j.jchromb.2015.05.015
127. Dumlao, D. S.; Buczynski, M. W.; Norris, P. C.; Harkewicz, R.; Dennis, E. A. High-throughput lipidomic analysis of fatty acid derived eicosanoids and N-acylethanolamines Biochim. Biophys. Acta, Mol. Cell Biol. Lipids 2011, 1811, 724-736 10.1016/j.bbalip.2011.06.005
128. Wang, D.; Dubois, R. N. Eicosanoids and cancer Nat. Rev. Cancer 2010, 10, 181-193 10.1038/nrc2809
129. Konya, V.; Marsche, G.; Schuligoi, R.; Heinemann, A. E-type prostanoid receptor 4 (EP4) in disease and therapy Pharmacol. Ther. 2013, 138, 485-502 10.1016/j.pharmthera.2013.03.006
130. Ganesh, T. Prostanoid receptor EP2 as a therapeutic target J. Med. Chem. 2014, 57, 4454-4465 10.1021/jm401431x
131. Celotti, F.; Laufer, S. Anti-inflammatory drugs: new multitarget compounds to face an old problem. The dual inhibition concept Pharmacol. Res. 2001, 43, 429-436 10.1006/phrs.2000.0784
132. Kulkarni, S. K.; Singh, V. P. Licofelone: the answer to unmet needs in osteoarthritis therapy? Curr. Rheumatol. Rep. 2008, 10, 43-48 10.1007/s11926-008-0008-7
133. Xu, B.; Mi, Y. Y.; Min, Z. C.; Cheng, G.; Tong, N.; Tao, J.; Li, P. C.; Wang, M. L.; Tang, J. L.; Zhang, Z. D.; Song, N. H.; Zhang, W.; Wu, H. F.; Feng, N. H.; Hua, L. X. p53 codon 72 increased biochemical recurrence risk after radical prostatectomy in a southern Chinese population Urol. Int. 2010, 85, 401-405 10.1159/000315991